PLUS THERAPEUTICS, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$0
Free Cash Flow Per Share
$-0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity
903.9%
Return on Assets
-195.0%
Return on Invested Capital
488.0%
Debt to Equity
—
Current Ratio
1.23
Quick Ratio
1.23
Asset Turnover
0.45
Days Sales Outstanding
—
Days Payables Outstanding
—
Days Inventory On Hand
—
Cash Conversion Cycle
—
R&D / Revenue
160.7%
SBC / Revenue
29.5%
Capex / Revenue
1.3%
Working Capital
$3M
Net Current Asset Value
$3M
Invested Capital
$4M
OCF / Net Income
0.93
FCF / Net Income
0.93
Accruals Ratio (Sloan)
-9.9%
Net Debt
$-9M
Net Debt / EBITDA
0.58
Interest Coverage
-27.92
Cash Coverage
-37.91
Capex Coverage
-310.07
Tangible Common Equity
$3M
TCE / Total Assets
20.2%
Goodwill / Total Assets
2.3%
NOPAT
$-12M
Cash ROIC
841.6%
WC / Revenue
54.8%
Capex / D&A
0.15
Reinvestment Rate
2.5%
Total Payout Ratio
-2.9%
Asset Growth vs Revenue Growth
156.6%
Revenue 5Y CAGR
—
Book Value 5Y CAGR
5.7%
Stock Price (FY-end)
$13
Market Cap
$992M
P/S Ratio
190.30
P/B Ratio
248.25
P/TB Ratio
301.43
Enterprise Value
$983M
EV / Sales
188.64
FCF Yield
-2.1%
Shareholder Yield
-0.2%
Buyback Yield
0.2%
R&D Yield
0.8%
Capex Yield
0.0%
Shares Variation (YoY)
910.3%
Beta (5Y)
0.75
Cost of Equity
8.3%
Cost of Debt (after tax)
—
52W High
$39
52W Low
$5
Trailing Return 1Y
-56.0%
Trailing Return 5Y
-98.4%
F-Score (Piotroski)
3.00
Z-Score (Altman)
1.47
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.